» Articles » PMID: 35961836

Male Osteoporosis-what Are the Causes, Diagnostic Challenges, and Management

Overview
Publisher Elsevier
Specialty Rheumatology
Date 2022 Aug 12
PMID 35961836
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is underrecognized and undertreated in men, even though up to 25% of fractures in patients over the age of 50 years occur in men. Men develop osteoporosis with normal aging and accumulation of comorbidities that cause bone loss. Secondary causes of bone loss may be found in up to 60% of men with osteoporosis. Mortality in men who experience major fragility fracture is greater than in women. Diagnosis of osteoporosis in men is similar to women, based on low-trauma or fragility fractures, and/or bone mineral density dual-energy X-ray absorptiometry (DXA) T-scores at or below -2.5. Because most clinical trials with osteoporosis drugs in men were based on bone density endpoints, not fracture reduction, the antifracture efficacy of approved treatments in men is not as well documented as that in women. Men at a high risk of fracture should be offered treatment to reduce future fractures.

Citing Articles

Mortality associated with osteoporosis and pathological fractures in the United States (1999-2020): a multiple-cause-of-death study.

Huo R, Wei C, Huang X, Yang Y, Huo X, Meng D J Orthop Surg Res. 2024; 19(1):568.

PMID: 39285484 PMC: 11406831. DOI: 10.1186/s13018-024-05068-1.


Clinical characteristics and risk factors of osteoporosis among older Asian men with type-2 diabetes mellitus, hypertension, or hyperlipidaemia.

Tan Y, Ng D, Gunasekaran K, Lim W, Tan N Arch Osteoporos. 2024; 19(1):83.

PMID: 39235564 PMC: 11377474. DOI: 10.1007/s11657-024-01442-y.


Application of Artificial Intelligence Methods on Osteoporosis Classification with Radiographs-A Systematic Review.

Liu R, Ong W, Makmur A, Kumar N, Low X, Shuliang G Bioengineering (Basel). 2024; 11(5).

PMID: 38790351 PMC: 11117497. DOI: 10.3390/bioengineering11050484.


Health belief model - male osteoporosis: a cross-sectional study.

Ercan S, Ince Parpucu T, Baskurt Z, Baskurt F Cent Eur J Public Health. 2023; 31(3):184-190.

PMID: 37934477 DOI: 10.21101/cejph.a7789.


Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Moon R, Reginster J, Al-Daghri N, Thiyagarajan J, Beaudart C, Bruyere O Osteoporos Int. 2023; 34(8):1283-1299.

PMID: 37351614 PMC: 10382414. DOI: 10.1007/s00198-023-06827-2.